Bio-Techne (NASDAQ:TECH) agrees to buy Exosome Diagnostics for $250M cash plus a contingent consideration of up to $325M based on certain future milestones.
President and CEO Charles Kummeth says the acquisition "positions Bio-Techne to be a leader in the rapidly-growing non-invasive liquid biopsy market."
The transaction will be financed through a combination of cash on hand and a revolving credit line that Bio-Techne expects to obtain before the deal closes.
Closing is expected in July or early August.
Source: Press Release
Subscribe for full text news in your inbox